Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
2008/08/05 by Winston Dunn, Ronghui Xu, Deborah L. Wingard +5 · 27 citations
Medicine · #Liver Disease Diagnosis and Treatment #Diabetes, Cardiovascular Risks, and Lipoproteins #Liver Disease and Transplantation
paper · doi:10.1111/j.1572-0241.2008.02034.x
Abstract
OBJECTIVE: Case series suggest that nonalcoholic fatty liver disease (NAFLD) is associated with increased all-cause and cardiovascular mortality. The current study compared the survival of subjects with and without suspected NAFLD in a population-based cohort, and placed the finding in the context of previously published case series. METHODS: Primary analysis assessed mortality for NHANES-III participants with and without suspected NAFLD using the National Death Index. Suspected NAFLD was based upon unexplained ALT elevation. The Olmsted County and Cleveland Clinic case series were also used for comparison. Survivals were compared using Proportional Hazards Model and direct age standardization. RESULTS: The NHANES cohort included 980 with and 6,594 subjects without suspected NAFLD. Over a mean of 8.7 yr, suspected NAFLD had a hazards ratio of 1.37 (95% CI 0.98-1.91) for all-cause mortality. In the 45-54 age group, suspected NAFLD had significantly higher all-cause (4.40 95% CI 1.27-13.23) and cardiovascular mortality (8.15, 95% CI 2.00-33.20) after adjusting for conventional cardiovascular risk factors. The age-standardized rate per 10,000 per year was 129 (95% CI 118-140) for the NHANES non-NAFLD cohort, 154 (95% CI 116-198) for the NHANES suspected NAFLD cohort, 214 (95% CI 157-279) for the Olmsted County series, and 426 (95% CI 298-573) for the Cleveland Clinic series. CONCLUSION: The magnitude of mortality risk in NAFLD depends on the setting and method of ascertainment. Suspected NAFLD in the 45-54 age group is a strong independent risk factor for cardiovascular death and warrants further cardiovascular risk management guidelines.
Cited by
- Genetic Basis for Sex Differences in Obesity and Lipid Metabolism
- Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
- Nonalcoholic fatty liver disease and cardiovascular risk. [europepmc]
- Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. [europepmc]
- Quantification of liver fat with magnetic resonance imaging. [europepmc]
- Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003-2004. [europepmc]
- Mitochondria and redox signaling in steatohepatitis. [europepmc]
- Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. [europepmc]
- Nonalcoholic fatty liver disease is associated with coronary artery calcification. [europepmc]
- The Framingham risk score and heart disease in nonalcoholic fatty liver disease. [europepmc]
- Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. [europepmc]
- Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. [europepmc]
- Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. [europepmc]
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. [europepmc]
- Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. [europepmc]
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. [europepmc]
- Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record. [europepmc]
- Natural History of Nonalcoholic Fatty Liver Disease. [europepmc]
- Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. [europepmc]
- Genetic Basis for Sex Differences in Obesity and Lipid Metabolism. [europepmc]
- The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. [europepmc]
- Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. [europepmc]
- A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease. [europepmc]
- Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. [europepmc]
- Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: A comparative randomized controlled trial. [europepmc]
- Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. [europepmc]
- NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. [europepmc]
Related